Law firm cites Phospho-Soda package change
The Laszlo & Associates law firm says C.B. Fleet Company has removed the "bowel cleanser" indication from the packaging for its nonprescription laxative after dozens of lawsuits were filed by people who suffered "acute renal failure and chronic kidney disease" after using the product as a bowel cleanser prior to colonoscopies and surgical procedures. In an Aug. 9 release, New York-based Laszlo says it is among the law firms representing clients from more than 20 states in suits against Lynchburg, Va.-based Fleet stemming from use of Phospho-Soda as a bowel cleanser. Following an FDA safety alert in May 2006, the firm recommended "follow the special instructions from your doctor exactly" when using its oral sodium phosphate products for bowel cleansing. FDA's announcement cited an association between bowel cleansers and acute phosphate nephropathy, a type of acute renal failure (1"The Tan Sheet" May 15, 2006, p. 10)...
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




